NDAINTRAVENOUSINJECTABLE
Approved
Jul 2001
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
DEFINITY RT (perflutren) by Lantheus Medical Imaging is ultrasound contrast activity [moa]. Approved for coronary artery disease, cardiac disease. First approved in 2001.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEFINITY RT (perflutren) is an intravenous ultrasound contrast agent approved in 2001 for enhancing cardiac imaging in patients with coronary artery disease and cardiac disease. It works by creating microbubbles that reflect ultrasound waves, improving visualization of the heart and coronary vessels during echocardiography.
Peak11.0 years to LOE
Product is at peak lifecycle with strong patent protection extending to 2037, suggesting stable commercial team size focused on maintenance and optimization.
Mechanism of Action
Ultrasound Contrast Activity
Pharmacologic Class:
Contrast Agent for Ultrasound Imaging
Indications (2)
Worked on DEFINITY RT at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.